A Phase 2 interventional study of Placebo and Midomafetamine HCl in Social Anxiety in Autistic Adults, sponsored by Lykos Therapeutics. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2025-06-05.
Sponsored by Lykos Therapeutics (part of Resilient Pharmaceuticals) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 603 studies in Autistic Disorder with a site in United States — 123 open to participants now, 152 under way, 3 of them phase 3. Autistic Disorder · United States.
Among the 603 studies in Autistic Disorder with a site in United States, this one is the 430th largest by enrollment of the 504 interventional ones that give a count, is one of 27 that started in 2014, is one of 95 in phase 2, and was the 246th registered.
1,034 studies on the registry are indexed under Autistic Disorder; 270 are open to participants now.
Browse Autistic Disorder studies →123 of the 603 studies in Autistic Disorder with a site in United States are open now. Recruiting first, the newest first:
Children's Mercy Hospital Kansas City · Sites in United States
Ages 8–12
Vanderbilt University Medical Center · Sites in United States
Ages 36 mo–72 mo
University of Wisconsin, Madison · Sites in United States
Massachusetts General Hospital · Sites in United States
Ages 7–17
Stony Brook University · Sites in United States
Ages 12–17
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
603 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 122 · Phase 3 43 · Phase 4 18
First in 1997; this study’s year is marked. 27 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 44 across the 504 interventional studies, 135 across the 96 observational. Of the 408 that completed or were terminated, 143 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 603 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lykos Therapeutics, one of the names counted as Resilient Pharmaceuticals. Under that name alone:
Lykos Therapeutics is the lead sponsor of 28 studies on the registry; 1 is open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Resilient Pharmaceuticals has 1 study filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
34 of the studies in Autistic Disorder with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02914951Yale UniversityCognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability | 2026-12 |
| NCT06627205Stanford UniversitySleep Restriction Therapy (SRT) for Sleep Problems in Children With Autism | 2026-12 |
| NCT04805957Rutgers, The State University of New JerseyValidation Digital Bio-markers During Sulforaphane Treatment. | 2026-12-01 |
| NCT07421830Northeastern UniversityAn Empowering Parent Training Intervention to Increase Physical Activity in Preschool Aged Children With Autism | 2026-12-31 |
| NCT02000284University of ArkansasMitochondrial Dysfunction in Autism Spectrum Disorder | 2026-12-31 |
Add all 34 to your calendar (.ics) → With an account.
Among the 603 studies in Autistic Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if MDMA-assisted therapy is safe and effective at reducing social anxiety in adults with autism.
The main questions it aims to answer are:
Researchers will compare two blinded sessions of MDMA-assisted therapy to two blinded sessions of placebo with therapy.
Participants will undergo three non-drug preparatory therapy sessions before the first blinded medication session. After each medication session, participants will undergo three non-drug integrative therapy sessions.
In Stage 2, participants who received placebo with therapy in the first two blinded sessions will be able to undergo two sessions with MDMA-assisted therapy.
The main objective of this study was to collect safety data to examine whether MDMA-assisted therapy was tolerated and to estimate symptom reduction in social anxiety and other psychiatric symptoms that are common in the adult autistic population as evaluated by standard clinical measures. The primary outcome measure was change in social anxiety symptoms as measured by the Liebowitz Social Anxiety Scale (LSAS) [Heimberg et al., 1999].
Each of the 12 subjects participated in two blinded experimental sessions, with either MDMA or placebo, which lasted seven hours. Before experimental sessions, participants underwent three separate hour-long preparatory sessions to learn what to expect and complete pre-treatment assignments. After each experimental session, participants underwent three separate hour-long integrative sessions to help integrate their experiences and insights from the experimental sessions.
This study was designed as a dose escalation study to assist with the exploration of safety and finding the most effective dose in this population. Upon enrollment, participants (Group 1) were randomized to receive one dose of either placebo or 75 mg of midomafetamine HCl. In the second experimental session one month later, Group 1 subjects randomized to MDMA escalated to 100 mg of midomafetamine HCl, unless contraindicated. The second group of subjects enrolled (Group 2) were randomized to receive one dose of either placebo or 100 mg of midomafetamine HCl. In the second experimental session one month later, Group 2 subjects randomized to MDMA escalated to 125 mg of midomafetamine HCl, unless contraindicated.
The blind was maintained through the six-month follow-up. In Stage 2 after the blind was broken, subjects who received placebo in Stage 1 were offered an open-label extension with two experimental sessions of MDMA-assisted therapy scheduled one month apart. Subjects received 75 mg of midomafetamine HCl in the first session and escalated to 125 mg of midomafetamine HCl in the second session, unless contraindicated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive inactive placebo during two psychotherapy sessions lasting approximately 7 hours.
Drug: Placebo · Behavioral: Therapy
Participants will receive 75 mg and 100 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
Drug: Midomafetamine HCl · Behavioral: Therapy
Participants will receive 100 mg and 125 mg midomafetamine HCl during two sessions of MDMA-assisted therapy, respectively, lasting approximately 7 hours.
Drug: Midomafetamine HCl · Behavioral: Therapy
Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapy.
Also known as: Inactive placebo
Participants in Group 1 receive 75 or 100 mg during the two experimental sessions and participants in Group 2 receive 100 or 125 mg during two experimental sessions.
Also known as: 3,4-methylenedioxymethamphetamine, MDMA
Therapy conducted throughout experimental sessions. Therapists will use a largely nondirective approach. There will be periods of structured and unstructured interactions. The structured interactions will be selected based on elements of therapeutic interventions that are currently in use in this population for the treatment of social anxiety.
Also known as: Manualized therapy
Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.
Time frame: 1-Month Post Experimental Session 2
Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.
Time frame: Baseline to 1-Month Post Experimental Session 2
Subjects were recruited by printed or internet advertisements, referrals from other health-care practitioners, and word-of-mouth. Potential participants were people, aged 21 or older, with a confirmed diagnosis of autism. The study was conducted at Los Angeles Biomedical Research Institute in Torrance, CA between February 2014 and October 2017.
| Milestone | Inactive Placebo With Psychotherapy | Group 1: MDMA-assisted Therapy 75mg/100mg | Group 2: MDMA-assisted Therapy 100mg/125mg |
|---|---|---|---|
| Started | 4 | 4 | 4 |
| Completed | 3 | 4 | 4 |
| Not completed | 1 | 0 | 0 |
| Milestone | Inactive Placebo With Psychotherapy | Group 1: MDMA-assisted Therapy 75mg/100mg | Group 2: MDMA-assisted Therapy 100mg/125mg |
|---|---|---|---|
| Started | 3 | 0 | 0 |
| Completed | 3 | 0 | 0 |
| Not completed | 0 | 0 | 0 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.
| score on a scale | Group 1: MDMA-assisted Therapy 75mg/100mg | Group 2: MDMA-assisted Therapy 100mg/125 mg | Inactive Placebo With Psychotherapy |
|---|---|---|---|
| Liebowitz Social Anxiety Scale (LSAS) Total Score 1-Month Post Experimental Session 2 | 34.3 ± 10.41 | 55.5 ± 11.47 | 64.0 ± 13.34 |
The LSAS is a 24-item, semi-structured interview on the severity of Social Anxiety Disorder. The LSAS separately assesses fear and avoidance of 24 social situations. The scale is divided into 2 subscales, 13 situations concerning performance anxiety, and 11 situations pertaining to social situations. The 24 items are first rated on a Likert Scale from 0 to 3 on fear felt during the situations, and then the same items are rated regarding avoidance of the situation. Combining the total scores for the Fear and Avoidance sections provides an overall score with a maximum of 144 points and a minimum of 0 points. The higher the score, the greater the anxiety symptoms. The overall scores are interpreted as: 55-65 is moderate, 65-80 is marked, 80-95 is severe, and greater than 95 is very severe social anxiety symptoms.
| score on a scale | Group 1: MDMA-assisted Therapy 75mg/100mg | Group 2: MDMA-assisted Therapy 100mg/125mg | Inactive Placebo With Psychotherapy |
|---|---|---|---|
| Change in Leibowitz Social Anxiety Scale (LSAS) Total Score From Baseline to 1-Month Post Experimental Session 2 | -51.0 ± 8.19 | -39.0 ± 17.57 | -19.3 ± 18.77 |
Collected over All AEs from baseline to the end of stage 2 (approximately 10 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1: MDMA-assisted Therapy 75mg/100mg | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Group 2: MDMA-assisted Therapy 100mg/125mg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Inactive Placebo With Psychotherapy (Stage 1) | 0/4 (0%) | 0/4 (0%) | 1/4 (25%) |
| Event | Group 1: MDMA-assisted Therapy 75mg/100mg | Group 2: MDMA-assisted Therapy 100mg/125mg | Inactive Placebo With Psychotherapy (Stage 1) |
|---|---|---|---|
| Depressed moodPsychiatric disorders | 0/4 | 2/4 | 0/4 |
| AnxietyPsychiatric disorders | 0/4 | 1/4 | 0/4 |
| Irritable bowel syndromeGastrointestinal disorders | 0/4 | 0/4 | 1/4 |
| SinusitisInfections and infestations | 0/4 | 0/4 | 1/4 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 1/4 | 1/4 |
| DepressionPsychiatric disorders | 1/4 | 0/4 | 1/4 |
| Suicidal ideationPsychiatric disorders | 1/4 | 1/4 | 1/4 |
| PainGeneral disorders | 0/4 | 1/4 | 0/4 |
| PyrexiaGeneral disorders | 0/4 | 1/4 | 0/4 |
| NasopharyngitisInfections and infestations | 0/4 | 1/4 | 0/4 |
Safety Set
| Age, Continuous(years) | Inactive Placebo With Psychotherapy | Group 1 MDMA-assisted Therapy 75mg/100mg | Group 2 MDMA-assisted Therapy 100mg/125mg | Total |
|---|---|---|---|---|
| Mean | 28.27 ± 3.77 | 37.93 ± 12.25 | 27.77 ± 5.87 | 31.32 ± 8.83 |
| Sex: Female, Male(Participants) | Inactive Placebo With Psychotherapy | Group 1 MDMA-assisted Therapy 75mg/100mg | Group 2 MDMA-assisted Therapy 100mg/125mg | Total |
|---|---|---|---|---|
| Female | 0 | 1 | 1 | 2 |
| Male | 4 | 3 | 3 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Inactive Placebo With Psychotherapy | Group 1 MDMA-assisted Therapy 75mg/100mg | Group 2 MDMA-assisted Therapy 100mg/125mg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 3 | 3 |
| Not Hispanic or Latino | 4 | 4 | 1 | 9 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Baseline Liebowitz Social Anxiety Scale (LSAS) Score(units on a scale) | Inactive Placebo With Psychotherapy | Group 1 MDMA-assisted Therapy 75mg/100mg | Group 2 MDMA-assisted Therapy 100mg/125mg | Total |
|---|---|---|---|---|
| Mean | 83.3 ± 11.87 | 89.0 ± 8.60 | 94.5 ± 22.13 | 88.9 ± 14.67 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We will share outcome data appearing in any published reports upon request.
Supporting information: Study protocol, Informed consent form
Time frame: Data and study-related documents will be available when all participants have completed the study
Access criteria: Interested persons should correspond with the central contact for the study.
Ran from Apr 2014 to primary completion in Apr 2017, 36 months.
Results were first posted in Oct 2020, 3 years 5 months after primary completion. A results delay was requested in Sep 2018.
Of 44 phase 2 interventional studies under Autistic Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 62. This study's 36 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: N-Methyl-3,4-methylenedioxyamphetamine